SU 11654

Known as: SU-11654, SU11654 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2013
01220022013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Murine cancer models have been extremely useful for analyzing the biology of pathways involved in cancer initiation, promotion… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2010
2010
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… (More)
Is this relevant?
Review
2010
Review
2010
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… (More)
Is this relevant?
Review
2009
Review
2009
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2008
2008
OBJECTIVE Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers. While Kit inhibitors have… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
OBJECTIVE To evaluate canine histiocytic sarcoma cell lines and tumor samples for dysregulation of the Kit/stem-cell factor (SCF… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2003
2003
PURPOSE The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2002
2002
Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?